Magdeburg-based RAYDIAX announced that it has raised €3.5M in a fresh round of funding to develop its computed tomography-based image assistance system for minimally invasive cancer treatments.
The funding includes a seed round of €2.4M led by HTGF and bmp Ventures with IBG funds, and a €1.1M top-up grant from the German Federal Ministry for Economic Affairs and Climate Action.
Capital utilisation
RAYDIAX plans to advance its preclinical prototype and enter the European and US markets.
Dr. Thomas Hoffmann, CEO and co-founder of RAYDIAX, says, “We pursue the goal of sustainably strengthening cancer therapy through high-tech medical technology. Minimally invasive image-guided interventions offer numerous advantages for patients.”
“With our targeted image-assistance system TACT, we are unleashing a completely new potential that will significantly expand the range of applications of these very gentle interventions, benefiting in particular patients for whom surgical cancer treatment appears to be too risky.”
Related: Kings Wins £1.5M for UKs First MedTech Company Builder
“With the closing of this financing round, we are in an optimal position to further develop our system in close coordination with our clinical partners, to accelerate market entry and to drive business growth,” adds Dr. Hoffmann.
Minimally invasive therapies in cancer care
According to RAYDIAX, minimally invasive therapies offer a promising solution for cancer patients, particularly the elderly or those in poor health, where traditional open-surgical methods are too risky.
By using thin instruments guided by imaging technology, these therapies target tumours with localised energy, minimising damage to surrounding tissues.
This approach enables faster patient recovery, reduces hospital stays, cuts costs, and enhances treatment capacity, addressing the challenges posed by cancer, especially in older and wealthier regions.
RAYDIAX is pioneering a groundbreaking imaging device, TACT, designed to assist with the precise planning, execution, and monitoring of minimally invasive cancer therapies.
This system, developed based on input from physicians across Europe, utilises X-ray-based computed tomography with minimised radiation exposure. The technology ensures sub-millimetre accuracy, enhancing safety for both patients and clinical staff during therapy.
